Taken together, these findings suggest a potential role for Gal-3 in the progression of IPF, and, as a consequence, this molecule may serve as a relevant therapeutic target for pulmonary fibrotic diseases, and its inhibition may improve disease outcomes [17]. This evidence concerns the gene LGALS3 and idiopathic pulmonary fibrosis.